IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
IGM Biosciences, Inc. (IGMS)
Last igm biosciences, inc. earnings: 3/26 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent developments. “We made significant progress during 2023 in the clinical development of our two lead product candidates in therapeutic areas that we believe have the greatest potential to produce significant near-term value,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. “Enrollment in our randomized clinical trial of aplitabart plus FOLFIRI and bevacizumab in second-line metastatic colorectal cancer continues to be encouraging, and we expect to expeditiously complete our target enrollment of 110 patients. If the control arm of this randomized study demonstrates the expected median progression free survival of approximately six months, we will be able to begin evaluating the benefit of aplitabart in enhancing progression free survival by the end of this year." Mr. Schwarzer continued, “We also in
Show less
Read more
Impact Snapshot
Event Time:
IGMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGMS alerts
High impacting IGM Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IGMS
News
- IGM Biosciences Insiders Placed Bullish Bets Worth US$992.2k [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences, Inc. (NASDAQ: IGMS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- IGM Biosciences Announces Refocusing of Sanofi Collaboration [Yahoo! Finance]Yahoo! Finance
- IGM Biosciences Announces Refocusing of Sanofi CollaborationGlobeNewswire
- IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology ForumGlobeNewswire
IGMS
Earnings
- 11/13/23 - Beat
IGMS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- IGMS's page on the SEC website